Risk of breast cancer among users of aspirin and other anti-inflammatory drugs.
We conducted a cohort study with a nested case-control analysis to evaluate the effect of anti-inflammatory drugs in breast cancer incidence using the General Practice Research Database. Women taking aspirin and paracetamol for 1 year or longer had an odds ratio (OR) of 0.77 (95 percent confidence interval (95% CI): 0.62,0.95) and 0.76 (95% CI: 0.65,0.88), respectively, compared to nonusers. Daily doses of aspirin (75 mg) and paracetamol (up to 2000 mg) showed the greatest reduced risk. Use of non-aspirin nonsteroidal anti-inflammatory drugs for more than 1 year was not associated with a reduced risk of breast cancer (OR=1.00 (95% CI: 0.84, 1.17), and the corresponding estimate among users with at least 2 years duration was similar. Our findings suggest that aspirin at cardioprophylactic doses as well as paracetamol at analgesic doses is associated with a reduced risk of breast cancer.
García Rodríguez
L A
LA
Centro Español de Investigación Farmacoepidemiológica (CEIFE), C/Almirante 28 2, 28004 Madrid, Spain.
González-Pérez
A
A
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D016022:Case-Control Studies; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008875:Middle Aged; D016017:Odds Ratio; D018570:Risk Assessment
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin